+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID06245122

Phase 1 Study of CS23546 to Assess Safety, Dosage, and Effects in Adults with Advanced Tumors

Led by Chipscreen Biosciences, Ltd. · Updated on 2026-04-06

156

Participants Needed

1

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and pharmacokinetics of CS23546 in adults with advanced tumors that are unresectable, recurrent, refractory, or for which no standard therapy is available. This open, single-arm phase I trial aims to determine the recommended phase 2 dose RP2D of CS23546 and study its effects on the body. Participants include those with various solid tumors or lymphomas, including specific cohorts with urothelial carcinoma, extranodal NKT-cell lymphoma, soft tissue sarcoma, and tumors with certain genetic markers. Participants receive CS23546 tablets orally in two main phases a dose escalation phase and a dose expansion phase. During dose escalation, participants receive a single ascending dose on day 1 followed by multiple ascending doses starting on day 7, with a 21-day observation period to monitor dose-limiting toxicities. Once the recommended dose is established, dose expansion begins with subjects grouped by tumor type or genetic markers to further assess the drug. Throughout the study, participants undergo evaluations including tumor tissue sampling for genetic markers, performance status assessments, and organ function tests. Researchers monitor dose-limiting toxicities, maximum tolerated dose, drug concentration over time, and immune markers up to cycle 5 each cycle being 21 days. Additional outcomes include response rates, disease control, progression measures, survival, and safety events up to 28 days after the last dose. The total study duration varies by participant based on dosing and follow-up requirements.

CONDITIONS

Brief Title

A Study of CS23546 in Subjects With Advanced Tumors

Research Team

X

Xinhao Wang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here